Literature DB >> 24859111

Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening.

Dolores Salas1, Mercedes Vanaclocha, Josefa Ibáñez, Ana Molina-Barceló, Vicente Hernández, Joaquín Cubiella, Raquel Zubizarreta, Montserrat Andreu, Cristina Hernández, Francisco Pérez-Riquelme, José Cruzado, Fernando Carballo, Luis Bujanda, Cristina Sarasqueta, Isabel Portillo, Mariola de la Vega-Prieto, Juan Diego Morillas, Vicente Valentín, Angel Lanas, Enrique Quintero, Antoni Castells.   

Abstract

PURPOSE: To compare two strategies for colorectal cancer screening: one-time colonoscopy versus fecal immunochemical testing (FIT) (and colonoscopy for positive) every 2 years, in order to determine which strategy provides the highest participation and detection rates in groups of sex and age.
METHODS: This analysis was performed with data from the first screening round within the COLONPREV study, a population-based, multicenter, nationwide trial carried out in Spain. Several logistic regression models were applied to identify the influence of the screening test on participation rates and detection of proximal and distal neoplasms, as well to identify the influence of age and sex: women aged 50-59 years, women aged 60-69 years, men aged 50-59 years, and men aged 60-69 years.
RESULTS: Participation was higher in women than in men, especially among women aged 50-59 years (25.91 % for colonoscopy and 35.81 % for FIT). Crossover from colonoscopy to FIT was higher among women than men, especially among those aged 60-69 years (30.37 %). In general, detection of any neoplasm and advanced adenoma was higher with colonoscopy than with FIT, but no significant differences were found between the two strategies for colorectal cancer detection. Detection of advanced adenoma in both arms was lower in women [specifically in women aged 50-59 years (OR 0.31; 95 % CI 0.25-0.38) than in men aged 60-69 years]. Women aged 50-59 years in the colonoscopy arm had a higher probability of detection of advanced adenoma (OR 4.49; 95 % CI 3.18-6.35), as well as of detection of neoplasms in proximal and distal locations (proximal OR 19.34; 95 % CI 12.07-31.00; distal OR 11.04; 95 % CI 8.13-15.01) than women of the same age in the FIT arm. These differences were also observed in the remaining groups but to a lesser extent.
CONCLUSION: Women were more likely to participate in a FIT-based strategy, especially those aged 50-59 years. The likelihood of detection of any neoplasm was higher in the colonoscopy arm for all the population groups studied, especially in women aged 50-59 years. Distinct population groups should be informed of the benefits of each screening strategy so that they may take informed decisions.

Entities:  

Mesh:

Year:  2014        PMID: 24859111     DOI: 10.1007/s10552-014-0398-y

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  10 in total

1.  Variation in colorectal cancer testing between primary care physicians: a cross-sectional study in Switzerland.

Authors:  Alexander Leonhard Braun; Emanuele Prati; Yonas Martin; Charles Dvořák; Kali Tal; Nikola Biller-Andorno; Jean-Luc Bulliard; Jacques Cornuz; Kevin Selby; Reto Auer
Journal:  Int J Public Health       Date:  2019-06-15       Impact factor: 3.380

Review 2.  Colorectal cancer screening and prevention in women.

Authors:  Lyssa Chacko; Carole Macaron; Carol A Burke
Journal:  Dig Dis Sci       Date:  2015-01-18       Impact factor: 3.199

Review 3.  Colorectal cancer screening: tests, strategies, and perspectives.

Authors:  Fabrizio Stracci; Manuel Zorzi; Grazia Grazzini
Journal:  Front Public Health       Date:  2014-10-27

4.  Diagnosis reliability of combined flexible sigmoidoscopy and fecal-immunochemical test in colorectal neoplasia screening.

Authors:  Dana Iovanescu; Mirela Frandes; Diana Lungeanu; Amelia Burlea; Bogdan P Miutescu; Eftimie Miutescu
Journal:  Onco Targets Ther       Date:  2016-11-04       Impact factor: 4.147

5.  Use of Insoluble Dietary Fiber and Probiotics for Bowel Preparation Before Colonoscopy: A Prospective Study.

Authors:  Kensuke Kudou; Koich Kimura; Ryosuke Tsutsumi; Naotaka Hashimoto; Hiroya Wada; Tetsuo Ikeda
Journal:  Surg Laparosc Endosc Percutan Tech       Date:  2022-02-24       Impact factor: 1.719

6.  Colorectal cancer screening with fecal immunochemical testing or primary colonoscopy: An analysis of health equity based on a randomised trial.

Authors:  U Strömberg; C Bonander; M Westerberg; L Å Levin; C Metcalfe; R Steele; L Holmberg; A Forsberg; R Hultcrantz
Journal:  EClinicalMedicine       Date:  2022-04-16

7.  Characteristics of nonparticipants in a randomised colorectal cancer screening trial comparing sigmoidoscopy and faecal immunochemical testing.

Authors:  Edoardo Botteri; Geir Hoff; Kristin R Randel; Øyvind Holme; Thomas de Lange; Tomm Bernklev; Eline Aas; Mona Berthelsen; Erik Natvig; Benedicte Kirkøen; Markus D Knudsen; Ane S Kvaerner; Anna L Schult; Giske Ursin; Anita Jørgensen; Paula Berstad
Journal:  Int J Cancer       Date:  2022-04-22       Impact factor: 7.316

8.  Predictors of Colorectal Cancer Screening Modality Among Newly Age-Eligible Medicaid Enrollees.

Authors:  Cynthia M Mojica; Bonnie Lind; Yifan Gu; Gloria D Coronado; Melinda M Davis
Journal:  Am J Prev Med       Date:  2020-11-19       Impact factor: 5.043

9.  Offering patients a choice for colorectal cancer screening: a quality improvement pilot study in a quality circle of primary care physicians.

Authors:  Yonas Martin; Leo Alexander Braun; Marc-Andrea Janggen; Kali Tal; Nikola Biller-Andorno; Cyril Ducros; Kevin Selby; Reto Auer; Adrian Rohrbasser
Journal:  BMJ Open Qual       Date:  2019-10-03

10.  Geospatial analysis of the influence of family doctor on colorectal cancer screening adherence.

Authors:  Fabrizio Stracci; Alessio Gili; Giulia Naldini; Vincenza Gianfredi; Morena Malaspina; Basilio Passamonti; Fortunato Bianconi
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.